Browse the evidence

Empagliflozin (10 mg/day) does not significantly reduce the primary composite endpoint of hospitalization for heart failure or death from any cause in patients hospitalized with acute myocardial infarction.

Empagliflozin (10 mg daily) did not significantly reduce the risk of heart failure hospitalization or death in patients recently hospitalized for a heart attack, according to the EMPACT-MI trial. However, secondary analyses suggested some benefits in reducing heart failure events.

Females exhibit higher GLP-1 receptor (GLP1R) expression in specific brain regions (PBN, AP/NTS) involved in processing aversive stimuli, which may explain their heightened sensitivity to GLP-1 agonist-induced nausea.

This finding suggests that women's brains may have more 'targets' for GLP-1 drugs in areas that control nausea, which is why side effects are more common. This is a biological fact, not a personal failing.

SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin) significantly slow the progression of diabetic kidney disease (DKD) and reduce cardiovascular events in patients with chronic kidney disease (CKD), regardless of baseline glycemic control or diabetes status.

If you have diabetes and kidney disease (or high cardiovascular risk), ask your doctor about SGLT2 inhibitors (like Jardiance, Farxiga, or Trjendi). These drugs protect your kidneys and heart, even if your blood sugar is already well-controlled. They are taken once daily. Be aware of potential genital yeast infections or, rarely, ketoacidosis, but these risks are generally manageable and outweighed by the protection they offer to your kidneys.

GLP-1 receptor agonists induce nausea and vomiting primarily by binding to GLP-1 receptors in the dorsal vagal complex (brainstem) and stimulating peripheral vagal nerve fibers, leading to delayed gastric emptying and increased gut-to-brain signaling.

Nausea from GLP-1 medications is not a sign of toxicity or damage. It is a predictable side effect caused by how the drug interacts with your brain and gut nerves. This is why starting with a low dose helps your body adapt. The feeling is temporary and manageable, and it does not mean the medication is harming you.

SGLT2 inhibitors (empagliflozin, dapagliflozin, canagliflozin) significantly reduce the risk of hospitalization for heart failure in patients with type 2 diabetes, independent of glycemic control.

If you have Type 2 Diabetes and are at risk for heart failure, ask your doctor about SGLT2 inhibitors (like empagliflozin or dapagliflozin). These drugs have been proven in large studies to significantly lower the risk of hospitalization for heart failure, even independent of their blood sugar-lowering effects. This is a key preventive strategy for heart health in diabetes.

Historical obesity pharmacotherapies utilizing thyroid hormones, sympathomimetics, and serotonergic agents were withdrawn due to severe cardiovascular, psychiatric, or oncological toxicity, despite demonstrating weight loss efficacy.

Do not use historical weight loss drugs like thyroid hormones, amphetamines, or fenfluramine. They are dangerous and have been withdrawn from the market due to severe side effects like heart damage and death. Modern treatments focus on safer mechanisms like GLP-1 agonists.

There is no head-to-head evidence to determine which drug class (THR-β vs Incretins) is superior for histological outcomes in MASH.

Both resmetirom and incretins work for MASH, but we don't know which is better for the liver itself because no study has compared them directly.

There is a strong correlation between online search trends and prescriptions for semaglutide (Wegovy) with a correlation coefficient of r = 0.97.

Monitoring online search trends can provide insights into public interest in obesity medications.

Use of GLP-1 receptor agonists (GLP-1 RAs) is associated with an increased incidence of diabetic retinopathy (DR) with a hazard ratio (HR) of 1.07 (95% CI, 1.03-1.11).

Clinicians should be aware of the increased risk of DR when prescribing GLP-1 RAs to patients with T2D.

GLP-1 RAs are not associated with progression to proliferative diabetic retinopathy (HR, 1.06; 95% CI, 0.97-1.15) or diabetic macular edema (HR, 0.98; 95% CI, 0.95-1.01) in patients with preexisting DR.

Patients with preexisting DR may not experience worsening of certain complications when treated with GLP-1 RAs.

In patients with cardiometabolic HFpEF, semaglutide showed a 42% lower risk of hospitalization for heart failure or all-cause mortality compared with sitagliptin.

Semaglutide may be a beneficial treatment option for patients with HFpEF and cardiometabolic conditions.

GIP antagonism has been shown to reduce the development of obesity in preclinical models.

GIP antagonism could be a potential strategy for obesity treatment.

Current clinical candidates, including GSBR-1290, CT-996, and ECC5004, offer substantial potential due to their oral bioavailability and favorable gastrointestinal tolerability.

Practitioners may consider these candidates for their potential benefits in treatment regimens.

GLP-1RAs probably have little or no effect on risk for thyroid cancer.

Practitioners should consider that GLP-1RAs may not significantly increase thyroid cancer risk based on current evidence.

GLP-1RAs may have little or no effect on pancreatic cancer risk.

Practitioners should be aware that GLP-1RAs may not significantly increase pancreatic cancer risk.

The number of incident GLP-1 RA users in France increased from 5117 in January 2017 to 15,193 in June 2023.

Healthcare providers should be aware of the significant increase in GLP-1 RA prescriptions.

Continuation of GLP-1RAs did not appear to be associated with an increased incidence of residual gastric contents during EGD.

Practitioners can consider continuing GLP-1RAs during EGD without increased risk of residual gastric contents.

The study highlights a persistently elevated pulmonary aspiration risk in patients receiving semaglutide.

Anesthesiologists should be cautious of the increased aspiration risk in patients on semaglutide during surgery.

GLP-1 receptor-based agonists and oral dipeptidyl peptidase-4 inhibitors are currently the only available treatments for metabolic diseases.

Practitioners should be aware that current treatment options are limited to GLP-1 receptor-based therapies.

Current GLP-1-based therapies face challenges such as high costs and the need for repeated administration.

Healthcare providers should consider these challenges when prescribing GLP-1 therapies.

Incidental exposure to incretin-based medications during early pregnancy is becoming more likely.

Clinicians should be aware of the risks of medication exposure in unplanned pregnancies.

GLP-1RA development traces a century of translational progress from gut hormones to multi-agonist therapeutics.

Understanding the historical context can inform current therapeutic approaches.

The application of injectable agents is hindered by adverse effects, high costs, and accessibility issues.

Practitioners should consider these barriers when recommending injectable therapies for obesity.

Future pharmacotherapeutic options, including combination therapies and gene therapy, may improve outcomes for patients with genetic obesity disorders.

Practitioners should stay informed about emerging therapies that may enhance treatment for genetic obesity.